Boris Jordan, founder and executive chairman of Curaleaf Holdings, Inc., discusses the recent recommendation by the Health and Human Services Department (HHS) to the Drug Enforcement Administration (DEA) regarding the rescheduling of cannabis. He believes that the DEA and FDA will also recommend moving to schedule three. Despite the unpredictable nature of politics, Jordan is optimistic about the chances of rescheduling and expects a significant rally in cannabis stocks as transparency on the issue increases.